{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"To determine the half-life (t1/2) of Artesunate (AS) following five consecutive days of self-administration of 200mg Artesunate vaginal inserts (pessaries) among healthy women. Mean Artesunate half-life (t1/2) (mins) will be submitted.","groups":[{"description":"Artesunate vaginal inserts/pessaries are used as a treatment for cervical precancerous lesions.\n\nArtesunate pessary: Subjects will use the study pessaries, placed in the vagina every day for 5 consecutive days.","id":"OG000","title":"Artesunate Vaginal Inserts/ Pessaries"}],"populationDescription":"The plasma half-life of Artesunate could not be estimated because the concentration versus time profiles did not reach an elimination phase (i.e., the concentration versus time profile did not decrease) from 0 to 8h post administration of intravaginal artesunate.","reportingStatus":"POSTED","timeFrame":"Day 5","title":"To Determine the Half-life (t1/2) of Artesunate (AS)","type":"SECONDARY"}